Dindar Çelik Fatma, Aksu Kurtuluş, Akkale Özgür, Çelik Tuğlu Hatice, Yağdıran Melis, Telli Onur, Vural Solak Gürgün Tuğçe, Çelik Enes
University of Health Sciences, Ankara Ataturk Sanatorium Training and Research Hospital, Department of Immunology and Allergy, Ankara, Türkiye.
University of Health Sciences, Ankara Ataturk Sanatorium Training and Research Hospital, Department of Pediatric Allergy and Immunology, Ankara, Türkiye.
World Allergy Organ J. 2025 Jan 17;18(2):101025. doi: 10.1016/j.waojou.2024.101025. eCollection 2025 Feb.
To present the characteristics of drug hypersensitivity reactions (DHR) among iron preparations and to describe the outcomes of rapid drug desensitization (RDD) and drug provocation tests (DPT) of ferric carboxymaltose (FCM).
The retrospective descriptive study comprised patients with hypersensitivy to iron supplements. Low-risk according to the index reaction with iron, 10 patients underwent a 4-step DPT with FCM; an 11-step RDD protocol was administered to 21 patients not classified as low-risk. RDD success was evaluated for each cycle separately, defining successful completion as the implementation of all steps in both RDD and DPT protocols without subsequent early and/or late reactions.
Among the 21 patients (mean age: 41.73 ± 10.98 years, all female) hypersensitive to iron underwent FCM RDD, 20 patients (95.2%) successfully completed FCM treatment with RDD. RDD failed in only 1 patient (4.8%). The total number of desensitization cycles was 29, of which 28 (96.5%) were successful. Urticaria was the most common breakthrough hypersensitivity reaction and observed in 7 (33.3%) patients. Ten patients received FCM with DPT. The iron replacement therapy for these 10 patients was successfully completed. Urticaria developed in 2 patients after the completion of DPT.
RDD is a dependable procedure facilitating the efficient delivery and completion of FCM treatments in patients with iron hypersensitivity. Additionally, FCM can be applied with DPT in low-risk patients.
介绍铁剂药物过敏反应(DHR)的特征,并描述羧基麦芽糖铁(FCM)快速药物脱敏(RDD)和药物激发试验(DPT)的结果。
这项回顾性描述性研究纳入了对铁补充剂过敏的患者。根据铁剂引发的反应风险较低,10例患者接受了FCM的4步DPT;21例未被归类为低风险的患者接受了11步RDD方案。分别评估每个周期的RDD成功率,将成功完成定义为在RDD和DPT方案中实施所有步骤,且无随后的早期和/或晚期反应。
在21例对铁过敏的患者(平均年龄:41.73±10.98岁,均为女性)中接受了FCM RDD,20例患者(95.2%)通过RDD成功完成了FCM治疗。仅1例患者(4.8%)RDD失败。脱敏周期总数为29个,其中28个(96.5%)成功。荨麻疹是最常见的突破性过敏反应,7例(33.3%)患者出现该反应。10例患者接受了FCM的DPT。这10例患者的铁替代治疗成功完成。DPT完成后,2例患者出现荨麻疹。
RDD是一种可靠的方法,有助于铁过敏患者高效地接受和完成FCM治疗。此外,FCM可用于低风险患者的DPT。